Chemotherapy-Free Targeted Anti-BCR-ABL+ Acute Lymphoblastic Leukemia Therapy May Benefit the Heart

SIMPLE SUMMARY: Risk-adapted multiagent chemotherapy has led to a remarkable improvement in the life expectancy of patients with acute lymphoblastic leukemia (ALL). Nevertheless, in high-risk subgroups such as BCR-ABL+ ALL, relapse rates remain high without allogeneic hematopoietic stem cell transpl...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirchhoff, Hanna, Ricke-Hoch, Melanie, Wohlan, Katharina, Pietzsch, Stefan, Karsli, Ümran, Erschow, Sergej, Zweigerdt, Robert, Ganser, Arnold, Eder, Matthias, Scherr, Michaela, Hilfiker-Kleiner, Denise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870618/
https://www.ncbi.nlm.nih.gov/pubmed/35205731
http://dx.doi.org/10.3390/cancers14040983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870618/
https://www.ncbi.nlm.nih.gov/pubmed/35205731
http://dx.doi.org/10.3390/cancers14040983

Ejemplares similares